Tasly Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.taslyus.com
Clinical Trials
17
Active:0
Completed:9
Trial Phases
4 Phases
Phase 1:4
Phase 2:3
Phase 3:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (31.3%)Not Applicable
4 (25.0%)Phase 1
4 (25.0%)Phase 2
3 (18.8%)A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome
Not Applicable
Not yet recruiting
- Conditions
- Tourette Syndrome in ChildrenTourette Syndrome in Adolescence
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05188274
- Locations
- 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States
Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette Syndrome
Not Applicable
Not yet recruiting
- Conditions
- Tourette Syndrome
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05183594
- Locations
- 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Phase 3
Completed
- Conditions
- Acute Mountain Sickness (AMS)
- Interventions
- Drug: T89 capsuleDrug: Placebo capsule
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 853
- Registration Number
- NCT04993729
- Locations
- 🇺🇸
Hypoxia Research Lab, UCSF Parnassus Campus, S-256, San Francisco, California, United States
🇨🇳Affiliated Hospital of Chengdu University of TCM, Chengdu, Sichuan, China
🇨🇳Tibet Autonomous Region People's Hospital, Lhasa, Tibet, China
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
- Conditions
- Covid19
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Registration Number
- NCT04646031
- Locations
- 🇺🇸
MultiCare Health System, Tacoma, Washington, United States
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
Not Applicable
Withdrawn
- Conditions
- Coronavirus Disease 2019Novel Coronavirus Pneumonia
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Registration Number
- NCT04285190
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found